Claims
- 1. A method of obscuring immune recognition of a transplant by a host mammal, comprising:providing a transplant suitable for implantation in a mammal; providing a hydrogel matrix, the matrix comprising gelatin, dextran, at least one nitric oxide inhibitor, and an effective amount of polar amino acids, the polar amino acids selected from the group consisting of arginine, lysine, histidine, glutamic acid, and aspartic acid; and encapsulating the transplant within the hydrogel matrix; said effective amount of polar amino acids being the amount necessary to increase the rigidity of the matrix and allow direct injection of the matrix with the transplant encapsulated therein into a host mammal without the need for further immunosuppression.
- 2. A method according to claim 1, further comprising implanting the transplant into a transplant site in a mammal.
- 3. A method according to claim 2, wherein said implanting step comprises injecting the transplant into the mammal.
- 4. A method according to claim 2, wherein said implanting step comprises implanting the transplant intramuscularly, subcutaneously, intra-organ, intravascularly, or intraperitoneally.
- 5. A method according to claim 1, wherein the transplant comprises tissue, the tissue comprising cells having cell surface proteins.
- 6. A method according to claim 5, wherein said encapsulating step comprises encapsulating the tissue within the hydrogel matrix such that the matrix binds to the cell surface proteins of the tissue.
- 7. A method according to claim 6, wherein the transplant further comprises a carrier device, the carrier device housing the encapsulated tissue.
- 8. A method according to claim 5, wherein the tissue comprises cells selected from the group consisting of lung cells, liver cells, kidney cells, thymus cells, thyroid cells, heart cells, brain cells, pancreatic islet cells, pancreatic acinar cells and mixtures thereof.
- 9. A method according to claim 5, wherein the tissue is derived from a different species than the host mammal.
- 10. A method according to claim 1, wherein the gelatin comprises denatured collagen fragments, the collagen fragments providing exposed polar groups.
- 11. A method according to claim 10, wherein the gelatin comprises about 0.01 to about 40 mM of denatured collagen.
- 12. A method according to claim 1, wherein the effective amount of polar amino acids comprises about 3 to about 150 mM of polar amino acids.
- 13. A method according to claim 12, wherein the effective amount of polar amino acids comprises about 10 to about 65 mM of polar amino acids.
- 14. A method according to claim 1, wherein the at least one nitric oxide inhibitor is selected from the group consisting of cysteine, L-arginine analogues, cystine, and heparin.
- 15. A method according to claim 1, wherein the at least one nitric oxide inhibitor comprises about 5 to about 500 μM of L-cysteine and about 5 to about 500 μM of an L-arginine analogue.
- 16. A method according to claim 15, wherein the L-arginine analogue is aminoguanidine.
- 17. A method according to claim 1, wherein the effective amount of polar amino acids comprises:about 2 to about 60 mM of L-glutarnic acid; about 0.5 to about 30 mM of L-lysine; and about 1 to about 40 mM of Larginine.
- 18. A method according to claim 17, wherein the effective amount of polar amino acids comprises:about 5 to about 40 mM of L-glutamic acid; about 1 to about 15 mM of L-lysine; and about 1 to about 30 mM of L-arginine.
- 19. A method according to claim 1, wherein the matrix further comprises a superoxide inhibitor.
- 20. A method according to claim 19, wherein the superoxide inhibitor is EDTA.
- 21. A method according to claim 2, further comprising applying a buffer medium to the transplant site prior to implanting the transplant, the buffer medium comprising at least one nitric oxide inhibitor.
- 22. A method according to claim 21, wherein the at least one nitric oxide inhibitor of the buffer medium comprises about 50 to about 300 μM of L-cysteine and about 15 to about 250 μM of an L-arginine analogue.
- 23. A method according to claim 21, wherein said applying step comprises applying about 10 to about 300 cc. of the buffer medium to the transplant site.
- 24. A method according to claim 21, further comprising applying a buffer medium to the transplant site after implanting the transplant, the buffer medium comprising at least one nitric oxide inhibitor.
- 25. A method according to claim 24, wherein the at least one nitric oxide inhibitor of the buffer medium comprises about 50 to about 300 μM of L-cysteine and about 15 to about 250 μM of an L-arginine analogue.
- 26. A method of obscuring immune recognition of a transplant by a host mammal, comprising:providing tissue suitable for use in a transplant, the tissue comprising cells having cell surface proteins; providing a hydrogel matrix, the matrix comprising gelatin, dextran, at least one nitric oxide inhibitor, and an effective amount of polar amino acids, the polar amino acids selected from the group consisting of arginine, lysine, histidine, glutarnic acid, and aspartic acid; encapsulating the tissue within the hydrogel matrix to form an encapsulated transplant, the matrix binding to the cell surface proteins of the tissue; applying a first amount of a buffer medium to a transplant site of a mammal, the buffer medium comprising at least one nitric oxide inhibitor; implanting the encapsulated transplant into the transplant site after application of the first amount of the buffer medium; and applying a second amount of the buffer medium to the transplant site after implanting the encapsulated transplant; said effective amount of polar amino acids being the amount necessary to increase the rigidity of the matrix and allow direct injection of the matrix with the transplant encapsulated therein into a host mammal without the need for further immunosuppression.
- 27. A method according to claim 26, wherein the at least one nitric oxide inhibitor of the buffer medium comprises about 50 to about 300 μM of L-cysteine and about 15 to about 250 μM of an L-arginine analogue.
- 28. A method according to claim 26, wherein the buffer medium further comprises a superoxide inhibitor.
- 29. A method according to claim 26, further comprising the step of applying the buffer medium to the transplant site about once a day for about one to about seven days following said implanting.
Parent Case Info
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 09/113,437, filed Jul. 10, 1998, now U.S. Pat. No. 6,231,881, which is a continuation of application Ser. No. 08/568,482, filed Dec. 7, 1995, now U.S. Pat. No. 5,834,005, which is a continuation-in-part of application Ser. No. 08/300,429, filed Sep. 2, 1994, now abandoned, which is a continuation-in-part of application Ser. No. 07/841,973, filed Feb. 24, 1992, now abandoned, which are incorporated herein by reference.
US Referenced Citations (24)
Foreign Referenced Citations (19)
Number |
Date |
Country |
4431598 |
Mar 1996 |
DE |
0 213 908 |
Mar 1987 |
EP |
03 363 125 |
Oct 1989 |
EP |
0 481 791 |
Apr 1992 |
EP |
0 526 756 |
Feb 1993 |
EP |
0 564 786 |
Oct 1993 |
EP |
9804681 |
Feb 1988 |
WO |
9109119 |
Dec 1991 |
WO |
9219195 |
Nov 1992 |
WO |
9300441 |
Jan 1993 |
WO |
9324112 |
Dec 1993 |
WO |
9403154 |
Feb 1994 |
WO |
94 08702 |
Apr 1994 |
WO |
9415589 |
Dec 1994 |
WO |
9514037 |
May 1995 |
WO |
9529231 |
Nov 1995 |
WO |
97 20569 |
Jun 1997 |
WO |
97 39107 |
Oct 1997 |
WO |
9816629 |
Apr 1998 |
WO |
Non-Patent Literature Citations (5)
Entry |
Donofrio, “The Effects of Growth Factors on Proliferation of Adult Porcine Islets In Vitro”, Department of Biology, East carolina University (May 1997). |
Hubbell, et al., “Tissue Engineering,” Chemical & Engineering News, (Mar. 13, 1995), pp. 42-54. |
Metrakos, et al., “Collagen Gel Matrix Promotes Islet Cell Proliferation”, Transplantation Proceedings, vol. 26, No. 6 (Dec. 1994) pp. 3349-3350. |
Mandel et al., “Organ Culture of Fetal Mouse and Fetal Human Pancreatic Islets for Allograftting,” Diabetes, vol. Suppl. 4 (Aug. 1982), pp. 39-47. |
Isner, et al., “Therapeutic Angiogensis”, Frontiers in Bioscience, vol. 3 (May 5, 1998) pp. 49-69. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/568482 |
Dec 1995 |
US |
Child |
09/113437 |
|
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09/113437 |
Jul 1998 |
US |
Child |
09/346212 |
|
US |
Parent |
08/300429 |
Sep 1994 |
US |
Child |
08/568482 |
|
US |
Parent |
07/841973 |
Feb 1992 |
US |
Child |
08/300429 |
|
US |